List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1765201/publications.pdf Version: 2024-02-01

		498	1013
700	74,333	132	243
papers	citations	h-index	g-index
713	713	713	77337
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma. American Surgeon, 2022, 88, 1153-1158.	0.4	4
2	Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy. Annals of Surgery, 2022, 276, e474-e482.	2.1	15
3	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	3.2	28
4	Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2022, 125, 425-436.	0.8	6
5	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	9.4	110
6	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. Breast Cancer Research and Treatment, 2022, 191, 423-430.	1.1	6
7	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Clinical Genitourinary Cancer. 2022. 20. 69-79.	0.9	2
8	Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival. Annals of Surgery, 2022, 275, 371-381.	2.1	4
9	Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?. Journal of Vascular and Interventional Radiology, 2022, 33, 308-315.e1.	0.2	6
10	Multi-institutional Validation Study of Cyst Fluid Protein Biomarkers in Patients With Cystic Lesions of the Pancreas. Annals of Surgery, 2022, 276, e129-e132.	2.1	5
11	An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans. European Journal of Cancer, 2022, 161, 138-147.	1.3	6
12	Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. JAMA Oncology, 2022, 8, 385.	3.4	44
13	Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases. Cancers, 2022, 14, 693.	1.7	14
14	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist, 2022, 27, 380-388.	1.9	12
15	Association of genomic profiles and survival in early onset and screeningâ€age colorectal cancer patients with liver metastases resected over 15 years. Journal of Surgical Oncology, 2022, 125, 880-888.	0.8	4
16	Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1195-1201.	1.1	4
17	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
18	Differentiation of mucinous cysts and simple cysts of the liver using preoperative imaging. Abdominal Radiology, 2022, 47, 1333-1340.	1.0	1

#	Article	IF	CITATIONS
19	Machine learning radiomics can predict early liver recurrence after resection of intrahepatic cholangiocarcinoma. Hpb, 2022, 24, 1341-1350.	0.1	7
20	CT radiomics to predict early hepatic recurrence after resection for intrahepatic cholangiocarcinoma. , 2022, , .		0
21	Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis?. Annals of Surgical Oncology, 2022, 29, 4962-4974.	0.7	11
22	ASO Visual Abstract: Recurrence After Resection of Pancreatic Cancer – Can Radiomics Predict Patients at Greatest Risk of LiverÂMetastasis?. Annals of Surgical Oncology, 2022, , .	0.7	0
23	Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment. European Journal of Cancer, 2022, 168, 25-33.	1.3	25
24	Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. Breast Cancer Research and Treatment, 2022, , .	1.1	0
25	PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine, 2022, 386, 2363-2376.	13.9	588
26	Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time?. Journal of the American College of Surgeons, 2022, 235, 294-304.	0.2	5
27	Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. JAMA Oncology, 2022, 8, 1352.	3.4	8
28	Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses. Annals of Surgical Oncology, 2022, 29, 6815-6826.	0.7	2
29	3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases. International Journal of Hyperthermia, 2022, 39, 880-887.	1.1	15
30	Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?. Annals of Surgery, 2021, 274, e980-e987.	2.1	22
31	Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2021, 274, 1051-1057.	2.1	43
32	Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor. Journal of Gastrointestinal Surgery, 2021, 25, 1828-1836.	0.9	10
33	Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study. Clinical Colorectal Cancer, 2021, 20, e82-e95.	1.0	45
34	Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy. Annals of Surgical Oncology, 2021, 28, 539-549.	0.7	9
35	Hepatocellular carcinoma in patients with no identifiable risk factors. Hpb, 2021, 23, 118-126.	0.1	4
36	Robotic Gastrectomy for Gastric Adenocarcinoma in the USA: Insights and Oncologic Outcomes in 220 Patients. Annals of Surgical Oncology, 2021, 28, 742-750.	0.7	23

#	Article	IF	CITATIONS
37	Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2021, 28, 817-825.	0.7	8
38	Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Abdominal Radiology, 2021, 46, 1607-1617.	1.0	4
39	Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients. Annals of Surgical Oncology, 2021, 28, 3685-3694.	0.7	3
40	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. Journal of Clinical Oncology, 2021, 39, 155-169.	0.8	65
41	Differences in Liver Parenchyma are Measurable with CT Radiomics at Initial Colon Resection in Patients that Develop Hepatic Metastases from Stage II/III Colon Cancer. Annals of Surgical Oncology, 2021, 28, 1982-1989.	0.7	15
42	Inferences About Drug Safety in PhaseÂIII Trials in Oncology: Examples From Advanced Prostate Cancer. Journal of the National Cancer Institute, 2021, 113, 553-561.	3.0	12
43	Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation?. Annals of Surgical Oncology, 2021, 28, 1328-1335.	0.7	2
44	Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. Annals of Surgery, 2021, 273, 128-138.	2.1	62
45	Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸ F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. Journal of Nuclear Medicine, 2021, 62, 1050-1056.	2.8	19
46	Symptom burden and willingness to participate: implications for herbal clinical trials in lung cancer. Annals of Palliative Medicine, 2021, 10, 1895-1903.	0.5	3
47	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. Annals of Surgical Oncology, 2021, 28, 4829-4838.	0.7	14
48	Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia, 2021, 35, 3268-3271.	3.3	21
49	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. Journal of Clinical Oncology, 2021, 39, 911-919.	0.8	34
50	Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Annals of Surgical Oncology, 2021, 28, 3532-3544.	0.7	17
51	Use of Ultrasmall Core-Shell Fluorescent Silica Nanoparticles for Image-Guided Sentinel Lymph Node Biopsy in Head and Neck Melanoma. JAMA Network Open, 2021, 4, e211936.	2.8	59
52	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. Annals of Surgical Oncology, 2021, 28, 7040-7050.	0.7	0
53	Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. Journal of Urology, 2021, 205, 1055-1062.	0.2	12
54	Early liver metastases after "failure―of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?. Hpb, 2021, 23, 601-608.	0.1	3

#	Article	IF	CITATIONS
55	Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood, 2021, 138, 531-543.	0.6	42
56	Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant <i>POLE/POLD1</i> Colon Cancer. JCO Precision Oncology, 2021, 5, 817-826.	1.5	18
57	Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. Clinical Cancer Research, 2021, 27, 4101-4108.	3.2	24
58	Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade. JCO Clinical Cancer Informatics, 2021, 5, 679-694.	1.0	5
59	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Annals of Surgery, 2021, 274, 894-901.	2.1	15
60	Treatment patterns and survival in patients with earlyâ€onset pancreatic cancer. Cancer, 2021, 127, 3566-3578.	2.0	20
61	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab. Cancer Discovery, 2021, 11, 2748-2763.	7.7	222
62	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clinical Cancer Research, 2021, 27, 5472-5481.	3.2	4
63	Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care. Clinical Cancer Research, 2021, 27, 5891-5899.	3.2	9
64	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	3.6	73
65	Timing of Complication and Failure to Rescue after Hepatectomy: Single-Institution Analysis of 28 Years of Hepatic Surgery. Journal of the American College of Surgeons, 2021, 233, 415-425.	0.2	10
66	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	5.8	15
67	Association between biopsy method and development of peritoneal metastases in perihilar cholangiocarcinoma. Hpb, 2021, , .	0.1	0
68	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Network Open, 2021, 4, e2133457.	2.8	16
69	Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?. Annals of Surgery, 2020, 271, 147-154.	2.1	82
70	Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1. Cell Metabolism, 2020, 31, 105-114.e3.	7.2	100
71	Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 188-195.	0.7	6
72	Radiomic feature reproducibility in contrast-enhanced CT of the pancreas is affected by variabilities in scan parameters and manual segmentation. European Radiology, 2020, 30, 195-205.	2.3	58

#	Article	IF	CITATIONS
73	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 60.	3.4	112
74	Dynamic contrastâ€enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. NMR in Biomedicine, 2020, 33, e4166.	1.6	19
75	Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases. Annals of Surgery, 2020, 272, 352-356.	2.1	21
76	Towards Wiser Use and Interpretation of <i>P</i> Values. Journal of Sexual Medicine, 2020, 17, 1-3.	0.3	3
77	Treatment of colorectal cancer in Subâ€5aharan Africa: Results from a prospective Nigerian hospital registry. Journal of Surgical Oncology, 2020, 121, 342-349.	0.8	14
78	Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: analysis of outcome and liver function at disease progression. Hpb, 2020, 22, 588-594.	0.1	3
79	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clinical Cancer Research, 2020, 26, 6464-6474.	3.2	16
80	Editorial: Clinical trial design in the era of COVID-19. Clinical Trials, 2020, 17, 465-466.	0.7	0
81	Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics. Clinical Cancer Research, 2020, 26, 5424-5437.	3.2	21
82	Measuring the temporal prognostic utility of a baseline risk score. Lifetime Data Analysis, 2020, 26, 856-871.	0.4	0
83	Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e566-e574.	2.2	13
84	ls minimally invasive surgery of lesions in the right superior segments of the liver justified? A multiâ€institutional study of 245 patients. Journal of Surgical Oncology, 2020, 122, 1428-1434.	0.8	14
85	Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases. Journal of Surgical Oncology, 2020, 122, 1536-1542.	0.8	2
86	Genetic and environmental determinants of human TCR repertoire diversity. Immunity and Ageing, 2020, 17, 26.	1.8	42
87	Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer. Cancer Research, 2020, 80, 4892-4903.	0.4	26
88	When Predictive Models Collide. JCO Clinical Cancer Informatics, 2020, 4, 547-550.	1.0	2
89	The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discovery, 2020, 10, 792-805.	7.7	71
90	Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nature Biomedical Engineering, 2020, 4, 272-285.	11.6	43

#	Article	IF	CITATIONS
91	Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research, 2020, 26, 147-158.	3.2	59
92	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature, 2020, 579, 130-135.	13.7	229
93	Addition of adjuvant hepatic artery infusion to systemic chemotherapy following resection of colorectal liver metastases is associated with reduced liverâ€related mortality. Journal of Surgical Oncology, 2020, 121, 1314-1319.	0.8	5
94	Optimized variable selection via repeated data splitting. Statistics in Medicine, 2020, 39, 2167-2184.	0.8	3
95	Multimodal radiomics and cyst fluid inflammatory markers model to predict preoperative risk in intraductal papillary mucinous neoplasms. Journal of Medical Imaging, 2020, 7, 1.	0.8	8
96	Statistical machine learning model to predict Oncotype DX risk category in women over age 50 Journal of Clinical Oncology, 2020, 38, 524-524.	0.8	0
97	Do differences in the microbiome explain early onset in colon cancer?. Journal of Clinical Oncology, 2020, 38, e16070-e16070.	0.8	3
98	Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. European Radiology, 2019, 29, 458-467.	2.3	10
99	A perioperative multidisciplinary care bundle reduces surgical site infections in patients undergoing synchronous colorectal and liver resection. Hpb, 2019, 21, 181-186.	0.1	8
100	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia, 2019, 33, 390-402.	3.3	44
101	Hypophosphatemia as a Predictor of Organâ€6pecific Complications Following Gastrointestinal Surgery: Analysis of 8034ÂPatients. World Journal of Surgery, 2019, 43, 385-394.	0.8	7
102	Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. Hpb, 2019, 21, 212-218.	0.1	36
103	Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation. Abdominal Radiology, 2019, 44, 3755-3763.	1.0	74
104	CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Abdominal Radiology, 2019, 44, 3148-3157.	1.0	37
105	Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. Hpb, 2019, 21, 1541-1551.	0.1	16
106	Perioperative Bundle to Reduce Surgical Site Infection after Pancreaticoduodenectomy: A Prospective Cohort Study. Journal of the American College of Surgeons, 2019, 228, 595-601.	0.2	14
107	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4889-4899.	1.8	26
108	Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors. Science Translational Medicine, 2019, 11, .	5.8	12

#	Article	IF	CITATIONS
109	Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1824-1832.	0.7	31
110	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. JNCI Cancer Spectrum, 2019, 3, pkz015.	1.4	16
111	There is still a place for significance testing in clinical trials. Clinical Trials, 2019, 16, 223-224.	0.7	13
112	The calibrated model-based concordance improved assessment of discriminative ability in patient clusters of limited sample size. Diagnostic and Prognostic Research, 2019, 3, 11.	0.8	6
113	A tutorial on Dirichlet process mixture modeling. Journal of Mathematical Psychology, 2019, 91, 128-144.	1.0	36
114	lmaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹ Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of Nuclear Medicine, 2019, 60, 1517-1523.	2.8	38
115	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS ONE, 2019, 14, e0215409.	1.1	7
116	Quality of life improves after palliative placement of percutaneous tunneled drainage catheter for refractory ascites in prospective study of patients with end-stage cancer. Palliative and Supportive Care, 2019, 17, 677-685.	0.6	2
117	Role of the Interval from Completion of Neoadjuvant Therapy to Surgery in Postoperative Morbidity in Patients with Locally Advanced Rectal Cancer. Annals of Surgical Oncology, 2019, 26, 2019-2027.	0.7	15
118	Variance prior specification for a basket trial design using Bayesian hierarchical modeling. Clinical Trials, 2019, 16, 142-153.	0.7	25
119	Radiogenomics of rectal adenocarcinoma in the era of precision medicine: A pilot study of associations between qualitative and quantitative MRI imaging features and genetic mutations. European Journal of Radiology, 2019, 113, 174-181.	1.2	38
120	Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. European Urology Oncology, 2019, 2, 166-173.	2.6	47
121	Molecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles. Science Advances, 2019, 5, eaax5208.	4.7	36
122	Neutrophil-to-Lymphocyte Ratio as a Predictor of Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreas, 2019, 48, 832-836.	0.5	14
123	Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. Clinical Colorectal Cancer, 2019, 18, 8-18.	1.0	31
124	Outcomes after Pancreatectomy with Routine Pasireotide Use. Journal of the American College of Surgeons, 2019, 228, 161-170e2.	0.2	20
125	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1631-1637.	1.2	5
126	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology, 2019, 152, 38-45.	0.6	18

#	Article	IF	CITATIONS
127	Regional differences in gallbladder cancer pathogenesis: Insights from a multiâ€institutional comparison of tumor mutations. Cancer, 2019, 125, 575-585.	2.0	34
128	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncology, 2019, 5, e185896.	3.4	347
129	Endoscopic versus percutaneous drainage of post-operative peripancreatic fluid collections following pancreatic resection. Hpb, 2019, 21, 434-443.	0.1	14
130	Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. Hpb, 2019, 21, 612-618.	0.1	34
131	Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer. European Radiology, 2019, 29, 1104-1113.	2.3	23
132	Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. European Radiology, 2019, 29, 1733-1742.	2.3	9
133	Comparing Objective and Subjective Bayes Factors for the Two-Sample Comparison: The Classification Theorem in Action. American Statistician, 2019, 73, 22-31.	0.9	5
134	Quantitative Non-Gaussian Intravoxel Incoherent Motion Diffusion-Weighted Imaging Metrics and Surgical Pathology for Stratifying Tumor Aggressiveness in Papillary Thyroid Carcinomas. Tomography, 2019, 5, 26-35.	0.8	7
135	Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?. Abdominal Radiology, 2018, 43, 2665-2672.	1.0	30
136	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. American Journal of Surgical Pathology, 2018, 42, 705-714.	2.1	61
137	A symptomâ€based model to predict colorectal cancer in lowâ€resource countries: Results from a prospective study of patients at high risk for colorectal cancer. Cancer, 2018, 124, 2766-2773.	2.0	15
138	Quantitative Imaging Features and Postoperative Hepatic Insufficiency: A Multi-Institutional Expanded Cohort. Journal of the American College of Surgeons, 2018, 226, 835-843.	0.2	7
139	MEF2C Phosphorylation Is Required forÂChemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2018, 8, 478-497.	7.7	59
140	Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreaticÂcancer. Hpb, 2018, 20, 597-604.	0.1	52
141	Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?. Surgery, 2018, 163, 1238-1244.	1.0	147
142	Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Annals of Surgical Oncology, 2018, 25, 1034-1042.	0.7	92
143	Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 449-459.	13.9	1,951
144	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncology, 2018, 4, 309.	3.4	146

#	Article	IF	CITATIONS
145	Percutaneous Microwave versus Radiofrequency Ablation of Colorectal LiverÂMetastases: Ablation with Clear Margins (A0) Provides the Best Local TumorÂControl. Journal of Vascular and Interventional Radiology, 2018, 29, 268-275.e1.	0.2	196
146	Progression Patterns in the Remnant Pancreas after Resection of Non-Invasive or Micro-Invasive Intraductal Papillary Mucinous Neoplasms (IPMN). Annals of Surgical Oncology, 2018, 25, 1752-1759.	0.7	31
147	PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	2.8	51
148	Immediate Postablation ¹⁸ F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases. Journal of Nuclear Medicine, 2018, 59, 1360-1365.	2.8	33
149	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology, 2018, 4, e180071.	3.4	404
150	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas. Annals of Surgery, 2018, 267, 157-163.	2.1	105
151	Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center. Journal of Oncology Pharmacy Practice, 2018, 24, 116-120.	0.5	10
152	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2018, 268, 340-347.	2.1	39
153	Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging. ACS Applied Materials & Interfaces, 2018, 10, 4379-4393.	4.0	40
154	Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 8.e17-8.e24.	0.8	36
155	External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: AÂPopulation-based Study. Clinical Genitourinary Cancer, 2018, 16, e59-e65.	0.9	1
156	Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdominal Radiology, 2018, 43, 1575-1582.	1.0	5
157	Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?. Abdominal Radiology, 2018, 43, 2113-2118.	1.0	5
158	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. Annals of Surgical Oncology, 2018, 25, 431-438.	0.7	76
159	Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217.	3.4	93
160	Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Annals of Surgery, 2018, 267, 898-904.	2.1	9
161	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	1.0	14
162	Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nature Communications, 2018, 9, 4141.	5.8	126

#	Article	IF	CITATIONS
163	Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017. Abdominal Radiology, 2018, 43, 2893-2902.	1.0	105
164	Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. Abdominal Radiology, 2018, 43, 3271-3278.	1.0	46
165	Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality. JAMA Oncology, 2018, 4, 1006.	3.4	3
166	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2018, 8, 958-971.	7.7	594
167	Influence of CT acquisition and reconstruction parameters on radiomic feature reproducibility. Journal of Medical Imaging, 2018, 5, 1.	0.8	61
168	A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC) Journal of Clinical Oncology, 2018, 36, 4092-4092.	0.8	6
169	Quantitative CT analysis for the preoperative prediction of pathologic grade in pancreatic neuroendocrine tumors. , 2018, , .		0
170	Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT) Journal of Clinical Oncology, 2018, 36, 3581-3581.	0.8	0
171	Inference for the difference in the area under the ROC curve derived from nested binary regression models. Biostatistics, 2017, 18, kxw045.	0.9	10
172	Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Annals of Surgery, 2017, 265, 185-191.	2.1	366
173	An efficient basket trial design. Statistics in Medicine, 2017, 36, 1568-1579.	0.8	82
174	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 33.e21-33.e26.	0.8	10
175	Operative morbidity and survival following hepatectomy for colorectal liver metastasis in octogenarians: a contemporary case matched series. Hpb, 2017, 19, 162-169.	0.1	21
176	Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 2017, 543, 113-117.	13.7	1,314
177	Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. Annals of Surgical Oncology, 2017, 24, 1835-1842.	0.7	61
178	Preoperative assessment of microvascular invasion in hepatocellular carcinoma. , 2017, , .		0
179	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics, 2017, 49, 866-875.	9.4	75
180	PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics, 2017, 49, 1005-1014.	9.4	69

MITHAT GöNEN

#	Article	IF	CITATIONS
181	Comparison of FDC-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1428-1437.	3.3	74
182	Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. Journal of Gastrointestinal Surgery, 2017, 21, 1254-1261.	0.9	24
183	18F–FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1420-1427.	3.3	40
184	High-Grade Serous Ovarian Cancer: Associations between <i>BRCA</i> Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology, 2017, 285, 472-481.	3.6	46
185	Prognostic and Predictive Ability of Tumor Sidedness. JAMA Oncology, 2017, 3, 1314.	3.4	7
186	The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide. Annals of Surgery, 2017, 265, 11-16.	2.1	53
187	Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2017, 24, 2482-2490.	0.7	45
188	Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2017, 163, 565-571.	1.1	77
189	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology, 2017, 62, 74-82.	1.1	17
190	Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2017, 24, 1358-1366.	0.7	86
191	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	2.9	74
192	Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis. Journal of the American College of Surgeons, 2017, 225, 778-788e1.	0.2	66
193	Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections. JAMA - Journal of the American Medical Association, 2017, 318, 1003.	3.8	8
194	Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2017, 24, 3706-3714.	0.7	62
195	Cancer-Targeting Ultrasmall Silica Nanoparticles for Clinical Translation: Physicochemical Structure and Biological Property Correlations. Chemistry of Materials, 2017, 29, 8766-8779.	3.2	58
196	Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for Enhanced Cancer-Directed Uptake in Melanoma: A Comparison of Radiolabeling Strategies. Chemistry of Materials, 2017, 29, 8269-8281.	3.2	59
197	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
198	Hypophosphatemia after Hepatectomy or Pancreatectomy: Role of the Nicotinamide Phosphoribosyltransferase. Journal of the American College of Surgeons, 2017, 225, 488-497e2.	0.2	17

#	Article	IF	CITATIONS
199	Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection. Annals of Surgery, 2017, 266, 693-701.	2.1	86
200	Should Patients With Cystic Lesions of the Pancreas Undergo Long-term Radiographic Surveillance?. Annals of Surgery, 2017, 266, 536-544.	2.1	66
201	Prospective Clinical Trial of ¹⁸ F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. Journal of Nuclear Medicine, 2017, 58, 1037-1042.	2.8	47
202	Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology, 2017, 176, 86-91.	1.2	29
203	Limited accuracy of DCE-MRI in identification of pathological complete responders after chemoradiotherapy treatment for rectal cancer. European Radiology, 2017, 27, 1605-1612.	2.3	24
204	Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. Annals of Surgery, 2017, 265, 158-165.	2.1	115
205	Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2017, 24, 202-210.	0.7	49
206	A Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon Cancer. Journal of Cancer, 2017, 8, 1113-1122.	1.2	22
207	Distance in cancer gene expression from stem cells predicts patient survival. PLoS ONE, 2017, 12, e0173589.	1.1	12
208	Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. PLoS ONE, 2017, 12, e0188022.	1.1	69
209	Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. Journal of Clinical Oncology, 2017, 35, 1938-1944.	0.8	112
210	Specifying the True- and False-Positive Rates in Basket Trials. JCO Precision Oncology, 2017, 1, 1-5.	1.5	7
211	Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. Journal of Clinical Oncology, 2017, 35, 271-273.	0.8	110
212	Reply to A. Braillon, M. Boulin et al, and JH. Zhong et al. Journal of Clinical Oncology, 2017, 35, 258-259.	0.8	1
213	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2017, 35, 139-140.	0.8	22
214	Reply to H. Zhang et al. Journal of Clinical Oncology, 2017, 35, 3266-3267.	0.8	0
215	Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget, 2017, 8, 66117-66127.	0.8	80
216	Right versus left: Impact of primary location on survival and cure in patients undergoing hepatic resection for metastatic colon cancer Journal of Clinical Oncology, 2017, 35, 664-664.	0.8	3

#	Article	IF	CITATIONS
217	Mutational profiling of resected intrahepatic cholangiocarcinoma Journal of Clinical Oncology, 2017, 35, e15675-e15675.	0.8	1
218	Poor prognosis in patients with resectable KRAS-MUT colorectal liver metastases is improved by adjuvant hepatic arterial infusion chemotherapy Journal of Clinical Oncology, 2017, 35, e15161-e15161.	0.8	0
219	Abstract 4888: Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors. , 2017, , .		0
220	Forward genetic screen of human transposase genomic rearrangements. BMC Genomics, 2016, 17, 548.	1.2	13
221	A new concordance measure for risk prediction models in external validation settings. Statistics in Medicine, 2016, 35, 4136-4152.	0.8	38
222	Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer, 2016, 122, 758-765.	2.0	138
223	Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2016, 113, 188-193.	0.8	115
224	Boomerang: A Method for Recursive Reclassification. Biometrics, 2016, 72, 995-1002.	0.8	0
225	Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Scientific Reports, 2016, 6, 21371.	1.6	58
226	Assessing Clinical Trial–Associated Workload in Community-Based Research Programs Using the ASCO Clinical Trial Workload Assessment Tool. Journal of Oncology Practice, 2016, 12, e536-e547.	2.5	12
227	Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. Radiology, 2016, 280, 949-959.	3.6	108
228	18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1937-1944.	3.3	53
229	Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. Annals of Surgical Oncology, 2016, 23, 2137-2145.	0.7	41
230	Robotic Liver Resection: A Caseâ€Matched Comparison. World Journal of Surgery, 2016, 40, 1422-1428.	0.8	86
231	Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. Surgery, 2016, 160, 67-73.	1.0	75
232	Time-to-Surgery and Survival Outcomes in Resectable Colorectal Liver Metastases: A Multi-Institutional Evaluation. Journal of the American College of Surgeons, 2016, 222, 766-779.	0.2	33
233	Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after 90Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. European Journal of Radiology, 2016, 85, 1224-1231.	1.2	47
234	Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nature Nanotechnology, 2016, 11, 977-985.	15.6	467

#	Article	IF	CITATIONS
235	Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. Journal of the American College of Surgeons, 2016, 223, 493-505e2.	0.2	101
236	Multiâ€institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusionâ€weighted MRI. Magnetic Resonance in Medicine, 2016, 75, 1708-1716.	1.9	50
237	The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. International Journal of Endocrine Oncology, 2016, 3, 203-219.	0.4	31
238	Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. American Journal of Roentgenology, 2016, 207, 661-670.	1.0	29
239	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	15.2	195
240	Prospective Randomized Controlled Trial of Liberal Vs Restricted Perioperative Fluid Management in Patients Undergoing Pancreatectomy. Annals of Surgery, 2016, 264, 591-598.	2.1	42
241	Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. Head and Neck, 2016, 38, E1192-9.	0.9	142
242	Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis. Annals of Surgery, 2016, 264, 147-154.	2.1	81
243	Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. EBioMedicine, 2016, 7, 94-99.	2.7	13
244	Symptomatic Perihepatic Fluid Collections After Hepatic Resection in the Modern Era. Journal of Gastrointestinal Surgery, 2016, 20, 748-756.	0.9	6
245	Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. Journal of Experimental Medicine, 2016, 213, 25-34.	4.2	25
246	A systematic selection method for the development of cancer staging systems. Statistical Methods in Medical Research, 2016, 25, 1438-1451.	0.7	5
247	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. Journal of Clinical Oncology, 2016, 34, 2359-2365.	0.8	60
248	An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. Thyroid, 2016, 26, 373-380.	2.4	173
249	Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. Journal of Clinical Oncology, 2016, 34, 2046-2053.	0.8	307
250	Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. JAMA Oncology, 2016, 2, 772.	3.4	34
251	Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case–Control Study. Annals of Surgical Oncology, 2016, 23, 1361-1370.	0.7	148
252	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. European Radiology, 2016, 26, 4303-4312.	2.3	63

#	Article	IF	CITATIONS
253	Initial Results of a Prospective Clinical Trial of ¹⁸ F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. Journal of Nuclear Medicine, 2016, 57, 1350-1356.	2.8	60
254	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. Journal of Nuclear Medicine, 2016, 57, 334-341.	2.8	16
255	A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2016, 22, 2575-2582.	3.2	40
256	Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes—A 10-year Experience at a Single Center. Radiology, 2016, 278, 601-611.	3.6	275
257	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. Annals of Surgical Oncology, 2016, 23, 410-415.	0.7	87
258	ReCAP: Impact of the National Cancer Institute Community Cancer Centers Program on Clinical Trial and Related Activities at a Community Cancer Center in Rural Nebraska. Journal of Oncology Practice, 2016, 12, 67-68.	2.5	31
259	Abstract CT118: Efficient basket trial designs. , 2016, , .		1
260	A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013) Journal of Clinical Oncology, 2016, 34, 1006-1006.	0.8	41
261	Obesity and breast cancer: Analysis of Breast Cancer Collaborative Registry (BCCR) data in a rural community cancer center Journal of Clinical Oncology, 2016, 34, e13103-e13103.	0.8	0
262	Potential cost savings by dose rounding monoclonal antibodies (mAB) in a community cancer center Journal of Clinical Oncology, 2016, 34, 6616-6616.	0.8	0
263	Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary. Translational Cancer Research, 2016, 5, S1299-S1301.	0.4	0
264	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. Blood, 2016, 128, 739-739.	0.6	0
265	Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 120-7.	1.0	28
266	Preoperative biliary drainage in perihilar cholangiocarcinoma: identifying patients who require percutaneous drainage after failed endoscopic drainage. Endoscopy, 2015, 47, 1124-1131.	1.0	41
267	MP63-20 DEVELOPMENT AND EXTERNAL VALIDATION OF A PATHOLOGICAL NODAL STAGING SCORE FOR PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2015, 193, .	0.2	0
268	Resection Margin and Survival in 2368 Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2015, 262, 476-485.	2.1	156
269	Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer. International Journal of Gynecological Cancer, 2015, 25, 1461-1467.	1.2	18
270	Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms. Annals of Surgery, 2015, 262, 1102-1107.	2.1	37

#	Article	IF	CITATIONS
271	Differences in gastric cancer survival between the U.S. and China. Journal of Surgical Oncology, 2015, 112, 31-37.	0.8	142
272	Prognostic Factors in Myoepithelial Carcinoma of Salivary Glands. American Journal of Surgical Pathology, 2015, 39, 931-938.	2.1	68
273	Evaluating agreement between solid tumor measurements used to assess response. Journal of Biomedical Graphics and Computing, 2015, 5, .	0.2	0
274	Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. PLoS ONE, 2015, 10, e0132953.	1.1	50
275	Meta-analysis of the technical performance of an imaging procedure: Guidelines and statistical methodology. Statistical Methods in Medical Research, 2015, 24, 141-174.	0.7	40
276	Central hepatectomy versus extended hepatectomy for liver malignancy: a matched cohort comparison. Hpb, 2015, 17, 1025-1032.	0.1	21
277	Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. Annals of Surgical Oncology, 2015, 22, 2761-2771.	0.7	79
278	Chemotherapy-Induced Splenic Volume Increase Is Independently Associated with Major Complications after Hepatic Resection for Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2015, 220, 271-280.	0.2	30
279	Positive Postoperative CEA is a Strong Predictor of Recurrence for Patients After Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 3087-3093.	0.7	34
280	Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?. Journal of Clinical Oncology, 2015, 33, 2221-2225.	0.8	35
281	Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. Journal of Vascular and Interventional Radiology, 2015, 26, 1112-1121.	0.2	8
282	Hepatic Parenchymal Preservation Surgery: Decreasing Morbidity and Mortality Rates in 4,152 Resections for Malignancy. Journal of the American College of Surgeons, 2015, 220, 471-479.	0.2	138
283	Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. Journal of the American College of Surgeons, 2015, 221, 452-461.	0.2	70
284	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 3512-3521.	0.7	135
285	Using Diffusion-Weighted MRI to Predict Aggressive Histological Features in Papillary Thyroid Carcinoma: A Novel Tool for Pre-Operative Risk Stratification in Thyroid Cancer. Thyroid, 2015, 25, 672-680.	2.4	33
286	Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biology, 2015, 16, 45.	3.8	145
287	Clinical Features and Outcome of Primary Pancreatic Lymphoma. Annals of Surgical Oncology, 2015, 22, 1176-1184.	0.7	36
288	Chemotherapy for Patients with Colorectal Liver Metastases Who Underwent Curative Resection Improves Long-Term Outcomes: Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2015, 22, 3070-3078.	0.7	53

#	Article	IF	CITATIONS
289	Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1666-1673.	3.3	79
290	Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment. Statistical Methods in Medical Research, 2015, 24, 27-67.	0.7	272
291	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2015, 33, 278-284.	0.8	102
292	Goal-Directed Fluid Therapy Using Stroke Volume Variation for Resuscitation after Low Central Venous Pressure-Assisted Liver Resection: A Randomized Clinical Trial. Journal of the American College of Surgeons, 2015, 221, 591-601.	0.2	62
293	Nomograms in oncology: more than meets the eye. Lancet Oncology, The, 2015, 16, e173-e180.	5.1	2,187
294	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285.	3.2	163
295	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28.	1.1	63
296	Comparison of ¹⁸ F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. Journal of Nuclear Medicine, 2015, 56, 1674-1680.	2.8	92
297	Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. Radiology, 2015, 277, 518-526.	3.6	23
298	Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That AffectÂOutcomes. Clinical Colorectal Cancer, 2015, 14, 296-305.	1.0	40
299	Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. American Journal of Surgery, 2015, 209, 935-942.	0.9	84
300	Repeatability Investigation of Reduced Field-of-View Diffusion-Weighted Magnetic Resonance Imaging on Thyroid Glands. Journal of Computer Assisted Tomography, 2015, 39, 1.	0.5	26
301	Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program. Journal of Clinical Investigation, 2015, 125, 1286-1298.	3.9	89
302	Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy Journal of Clinical Oncology, 2015, 33, 509-509.	0.8	22
303	Quality of life in RCT of pasireotide to reduce pancreatic complications following resection Journal of Clinical Oncology, 2015, 33, 393-393.	0.8	0
304	The management of small asymptomatic pancreatic neuroendocrine tumors: A matched case-control study Journal of Clinical Oncology, 2015, 33, 239-239.	0.8	0
305	Cancer Genetic Counseling Services (GCS) at Saint Francis Cancer Treatment Center (SFCTC) Journal of Clinical Oncology, 2015, 33, e12506-e12506.	0.8	0
306	Integrative Analysis of the Mutational Landscape of Mouse and Human AML Identifies Functionally Relevant Leukemia Disease Alleles. Blood, 2015, 126, 1247-1247.	0.6	0

#	Article	IF	CITATIONS
307	Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. Blood, 2015, 126, 1422-1422.	0.6	Ο
308	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. Blood, 2015, 126, 88-88.	0.6	0
309	89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2093-2105.	3.3	130
310	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Science Translational Medicine, 2014, 6, 260ra149.	5.8	589
311	Histone Modifications Are Associated with Transcript Isoform Diversity in Normal and Cancer Cells. PLoS Computational Biology, 2014, 10, e1003611.	1.5	22
312	Pasireotide for Postoperative Pancreatic Fistula. New England Journal of Medicine, 2014, 370, 2014-2022.	13.9	353
313	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. Radiology, 2014, 271, 220-229.	3.6	88
314	Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Human Pathology, 2014, 45, 2430-2436.	1.1	41
315	Timing of elective surgery as a perioperative outcome variable: analysis of pancreaticoduodenectomy. Hpb, 2014, 16, 250-262.	0.1	23
316	Predicting recurrence patterns after resection of hepatocellular cancer. Hpb, 2014, 16, 943-953.	0.1	54
317	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nature Genetics, 2014, 46, 424-426.	9.4	291
318	Readmission After Pancreatic Resection: Causes and Causality Pattern. Annals of Surgical Oncology, 2014, 21, 4342-4350.	0.7	46
319	Oncogenic Function of SCCRO5/DCUN1D5 Requires Its Neddylation E3 Activity and Nuclear Localization. Clinical Cancer Research, 2014, 20, 372-381.	3.2	16
320	American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. Hpb, 2014, 16, 1074-1082.	0.1	46
321	Factors Affecting Periprocedural Morbidity and Mortality and Long-term Patient Survival after Arterial Embolization of Hepatic Neuroendocrine Metastases. Journal of Vascular and Interventional Radiology, 2014, 25, 22-30.	0.2	37
322	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. Cell Reports, 2014, 6, 514-527.	2.9	239
323	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 24-29.	0.2	15
324	PET quantification with a histogram derived total activity metric: Superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nuclear Medicine and Biology, 2014, 41, 410-418.	0.3	33

#	Article	IF	CITATIONS
325	Stage-Stratified Prognosis of Signet Ring Cell Histology in Patients Undergoing Curative Resection for Gastric Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 1678-1685.	0.7	103
326	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. Journal of Clinical Oncology, 2014, 32, 513-518.	0.8	375
327	Vaccinia virus GLVâ€1h153 in combination with ¹³¹ I shows increased efficiency in treating tripleâ€negative breast cancer. FASEB Journal, 2014, 28, 676-682.	0.2	33
328	Genetic and Phenotypic Diversity in Breast Tumor Metastases. Cancer Research, 2014, 74, 1338-1348.	0.4	161
329	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. Journal of the National Cancer Institute, 2014, 106, .	3.0	179
330	Retrospective Analysis of ¹⁸ F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years. Journal of Nuclear Medicine, 2014, 55, 1578-1583.	2.8	87
331	FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma. Journal of the American College of Surgeons, 2014, 219, e176.	0.2	0
332	False-Positive [¹⁸ F]Fluorodeoxyglucose-Avid Lymph Nodes on Positron Emission Tomography–Computed Tomography After Allogeneic but Not Autologous Stem-Cell Transplantation in Patients With Lymphoma. Journal of Clinical Oncology, 2014, 32, 51-56.	0.8	22
333	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal of Clinical Oncology, 2014, 32, 1277-1280.	0.8	354
334	A comparison of colorectal cancer in Nigerian and North American patients: Is the cancer biology different?. Surgery, 2014, 156, 305-310.	1.0	39
335	Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 2014, 6, 224ra25.	5.8	2,069
336	ls Gastric Cancer Different in Korea and the United States? Impact of Tumor Location on Prognosis. Annals of Surgical Oncology, 2014, 21, 2332-2339.	0.7	57
337	Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials. Annals of Surgical Oncology, 2014, 21, 2675-2683.	0.7	38
338	A Retrospective Comparison of Microwave Ablation vs. Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. Annals of Surgical Oncology, 2014, 21, 4278-4283.	0.7	151
339	Remnant Growth Rate after Portal Vein Embolization Is a Good Early Predictor of Post-Hepatectomy Liver Failure. Journal of the American College of Surgeons, 2014, 219, 620-630.	0.2	84
340	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. European Urology, 2014, 66, 439-446.	0.9	24
341	Performance of a Nomogram Predicting Disease-Specific Survival After an RO Resection for Gastric Cancer in Patients Receiving Postoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 624-629.	0.4	13
342	MP56-07 COMPARISON OF THE EORTC TABLES AND THE NEWLY INTRODUCED EAU CATEGORIES FOR RISK STRATIFICATION OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER. Journal of Urology, 2014, 191, .	0.2	0

#	Article	IF	CITATIONS
343	MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS. Journal of Urology, 2014, 191, .	0.2	Ο
344	Residual Disease Predicts Outcomes after Definitive Resection for Incidental Gallbladder Cancer. Journal of the American College of Surgeons, 2014, 219, 416-429.	0.2	65
345	A Prospective Study of 18FDC-PET With CT Coregistration for Radiation Treatment Planning of Lymphomas and Other Hematologic Malignancies. International Journal of Radiation Oncology Biology Physics, 2014, 89, 376-383.	0.4	18
346	Liver Planning Software Accurately Predicts Postoperative Liver Volume and Measures Early Regeneration. Journal of the American College of Surgeons, 2014, 219, 199-207.	0.2	62
347	Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica, 2014, 99, 1701-1709.	1.7	18
348	DNA Mismatch Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas. Pancreas, 2014, 43, 1264-1270.	0.5	34
349	Endogenous Antibodies for Tumor Detection. Scientific Reports, 2014, 4, 5088.	1.6	7
350	Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities. Blood, 2014, 124, 1016-1016.	0.6	7
351	Evaluation of PET response to neoadjuvant therapy for patients with gastric and GEJ adenocarcinoma Journal of Clinical Oncology, 2014, 32, 114-114.	0.8	Ο
352	Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis Journal of Clinical Oncology, 2014, 32, 432-432.	0.8	0
353	Infiltrating neutrophils and malignant progression in intraductal papillary mucinous neoplasms (IPMN): An opportunity for identification of high-risk disease Journal of Clinical Oncology, 2014, 32, 4137-4137.	0.8	1
354	Impact of the NCI Community Cancer Centers Program (NCCCP) on clinical trial (CT) activities in a community cancer center in rural Nebraska Journal of Clinical Oncology, 2014, 32, 6511-6511.	0.8	0
355	Abstract LB-91: SMARCA4 mutations in small cell carcinoma of the ovary. , 2014, , .		Ο
356	Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression. Blood, 2014, 124, 1954-1954.	0.6	0
357	Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program. Blood, 2014, 124, 836-836.	0.6	Ο
358	Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nature Biotechnology, 2013, 31, 928-933.	9.4	362
359	The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience. Transplant International, 2013, 26, 990-998.	0.8	39
360	Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2013, 20, 4312-4321.	0.7	55

#	Article	lF	CITATIONS
361	Conversion to Complete Resection and/or Ablation Using Hepatic Artery Infusional Chemotherapy in Patients with Unresectable Liver Metastases from Colorectal Cancer: A Decade of Experience at a Single Institution. Annals of Surgical Oncology, 2013, 20, 2901-2907.	0.7	49
362	An assessment of estimation methods for generalized linear mixed models with binary outcomes. Statistics in Medicine, 2013, 32, 4550-4566.	0.8	49
363	Ki 67 is an Independent Predictive Biomarker of Cancer Specific and Local Recurrence-Free Survival After Lung Tumor Ablation. Annals of Surgical Oncology, 2013, 20, 676-683.	0.7	40
364	The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 701-707.	3.3	2
365	Pattern of Retained Contrast on Immediate Postprocedure Computed tomography (CT) After Particle Embolization of Liver Tumors Predicts Subsequent Treatment Response. CardioVascular and Interventional Radiology, 2013, 36, 1030-1038.	0.9	32
366	Margin Size is an Independent Predictor of Local Tumor Progression After Ablation of Colon Cancer Liver Metastases. CardioVascular and Interventional Radiology, 2013, 36, 166-175.	0.9	262
367	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. Journal of Urology, 2013, 189, 468-473.	0.2	40
368	Image-guided Thermal Ablation of Tumors Increases the Plasma Level of Interleukin-6 and Interleukin-10. Journal of Vascular and Interventional Radiology, 2013, 24, 1105-1112.	0.2	125
369	Hepatic Pedicle Clamping During Hepatic Resection for Colorectal Liver Metastases: No Impact on Survival or Hepatic Recurrence. Annals of Surgical Oncology, 2013, 20, 285-294.	0.7	38
370	Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2013, 20, 946-955.	0.7	141
371	Regional Differences in Gallbladder Cancer Pathogenesis: Insights from a Comparison of Cell Cycle-Regulatory, PI3K, and Pro-Angiogenic Protein Expression. Annals of Surgical Oncology, 2013, 20, 1470-1481.	0.7	10
372	Splenectomy to treat splenic lesions: An analysis of 148 cases at a cancer center. Journal of Surgical Oncology, 2013, 108, 521-525.	0.8	19
373	Predicting Dysplasia and Invasive Carcinoma in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Development of a Preoperative Nomogram. Annals of Surgical Oncology, 2013, 20, 4348-4355.	0.7	87
374	Cancer-testis gene expression is associated with the methylenetetrahydrofolate reductase 677 C>T polymorphism in non-small cell lung carcinoma. BMC Medical Genetics, 2013, 14, 97.	2.1	5
375	Selecting Patients for Acute Normovolemic Hemodilution during Hepatic Resection: A Prospective Randomized Evaluation of Nomogram-Based Allocation. Journal of the American College of Surgeons, 2013, 217, 210-220.	0.2	16
376	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. European Urology, 2013, 63, 848-854.	0.9	198
377	Impact of Obesity on Perioperative Complications and Long-term Survival of Patients with Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 780-787.	0.7	107
378	Intraoperative fluid management and complications following pancreatectomy. Journal of Surgical Oncology, 2013, 107, 529-535.	0.8	30

#	Article	IF	CITATIONS
379	Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 3525-3530.	0.8	223
380	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	0.9	47
381	Preoperative Chemotherapy and the Risk of Hepatotoxicity and Morbidity after Liver Resection for Metastatic Colorectal Cancer: A Single Institution Experience. Journal of the American College of Surgeons, 2013, 216, 41-49.	0.2	77
382	The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecologic Oncology, 2013, 129, 586-592.	0.6	40
383	1068 ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA WITH MUTATIONS OF EPIGENETIC REGULATORS BAP1 AND SETD2. Journal of Urology, 2013, 189, .	0.2	0
384	Mixtures of Receiver Operating Characteristic Curves. Academic Radiology, 2013, 20, 831-837.	1.3	5
385	Comparing ROC curves derived from regression models. Statistics in Medicine, 2013, 32, 1483-1493.	0.8	62
386	Management of hepatocellular adenoma: comparison of resection, embolization and observation. Hpb, 2013, 15, 235-243.	0.1	46
387	Role of Repeat Staging Laparoscopy in Locoregionally Advanced Gastric or Gastroesophageal Cancer after Neoadjuvant Therapy. Annals of Surgical Oncology, 2013, 20, 548-554.	0.7	26
388	Long-term Outcomes Following Tumor Ablation for Treatment of Bilateral Colorectal Liver Metastases. JAMA Surgery, 2013, 148, 597.	2.2	84
389	Comparison of diseaseâ€specific survival in the United States and Korea after resection for earlyâ€stage nodeâ€negative gastric carcinoma. Journal of Surgical Oncology, 2013, 107, 634-640.	0.8	36
390	Conditional Probability of Survival Nomogram for 1-, 2-, and 3-Year Survivors After an RO Resection for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 1623-1630.	0.7	60
391	Detailed Pathologic Characteristics of the Primary Colorectal Tumor Independently Predict Outcome after Hepatectomy for Metastases. Annals of Surgical Oncology, 2013, 20, 148-154.	0.7	43
392	What is the Significance of the Circumferential Margin in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy?. Annals of Surgical Oncology, 2013, 20, 1179-1184.	0.7	66
393	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a ¹ H MRS study. NMR in Biomedicine, 2013, 26, 204-212.	1.6	5
394	A simple decision analytic solution to the comparison of two binary diagnostic tests. Statistics in Medicine, 2013, 32, 1865-1876.	0.8	13
395	Correction of Data Reporting Errors. Radiology, 2013, 269, 949-950.	3.6	0
396	Testing the incremental predictive accuracy of new markers. Clinical Trials, 2013, 10, 690-692.	0.7	7

#	Article	IF	CITATIONS
397	Visualizing Longitudinal Data With Dropouts. American Statistician, 2013, 67, 97-103.	0.9	1
398	Dynamic prognostication using conditional survival estimates. Cancer, 2013, 119, 3589-3592.	2.0	94
399	Optimal Cutpoint Estimation With Censored Data. Journal of Statistical Theory and Practice, 2013, 7, 345-359.	0.3	8
400	Does preâ€operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase postâ€operative morbidity? A caseâ€matched analysis. Hpb, 2013, 15, 574-580.	0.1	34
401	Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. Hpb, 2013, 15, 803-813.	0.1	44
402	Biliary Self-Expandable Metal Stents Do Not Adversely Affect Pancreaticoduodenectomy. American Journal of Gastroenterology, 2013, 108, 1168-1173.	0.2	77
403	Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i> : A Report by MSKCC and the KIRC TCGA Research Network. Clinical Cancer Research, 2013, 19, 3259-3267.	3.2	301
404	Quality of Life After Gastrectomy for Adenocarcinoma. Annals of Surgery, 2013, 257, 1039-1046.	2.1	125
405	Comparing Primary Tumors and Metastatic Nodes in Head and Neck Cancer Using Intravoxel Incoherent Motion Imaging. Journal of Computer Assisted Tomography, 2013, 37, 346-352.	0.5	42
406	A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis. Annals of Surgery, 2013, 258, 347-353.	2.1	222
407	Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma. Blood, 2013, 122, 755-755.	0.6	1
408	Prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer Journal of Clinical Oncology, 2013, 31, 507-507.	0.8	4
409	A randomized single blind controlled trial of beads versus doxorubicin-eluting beads for arterial embolization of hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2013, 31, 143-143.	0.8	7
410	Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity , 2013, , .		0
411	Image-Guided Po ₂ Probe Measurements Correlated with Parametric Images Derived from ¹⁸ F-Fluoromisonidazole Small-Animal PET Data in Rats. Journal of Nuclear Medicine, 2012, 53, 1608-1615.	2.8	34
412	Evolutionary Pathways in BRCA1-Associated Breast Tumors. Cancer Discovery, 2012, 2, 503-511.	7.7	116
413	Treadmill Exercise Inducing Mild to Moderate Ischemia Has No Significant Effect on Skeletal Muscle or Cardiac 18F-FDG Uptake and Image Quality on Subsequent Whole-Body PET Scan. Journal of Nuclear Medicine, 2012, 53, 917-921.	2.8	7
414	Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System. American Journal of Surgical Pathology, 2012, 36, 1761-1770.	2.1	232

#	Article	IF	CITATIONS
415	Laparoscopic Versus Open Distal Gastrectomy for Gastric Cancer. Annals of Surgery, 2012, 255, 446-456.	2.1	325
416	Rate of Residual Disease After Complete Endoscopic Resection of Malignant Colonic Polyp. Diseases of the Colon and Rectum, 2012, 55, 122-127.	0.7	75
417	Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica, 2012, 97, 1553-1561.	1.7	39
418	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 2012, 120, 2297-2306.	0.6	92
419	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 2012, 44, 1179-1181.	9.4	692
420	Reliability of adverse symptom event reporting by clinicians. Quality of Life Research, 2012, 21, 1159-1164.	1.5	186
421	The Blumgart Preoperative Staging System for Hilar Cholangiocarcinoma: Analysis of Resectability and Outcomes in 380 Patients. Journal of the American College of Surgeons, 2012, 215, 343-355.	0.2	184
422	1400 CLINICAL NODAL STAGING SCORES FOR BLADDER CANCER A NEW PREOPERATIVELY NODAL ASSESSMENT TOOL. Journal of Urology, 2012, 187, .	0.2	0
423	Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?. Annals of Surgical Oncology, 2012, 19, 2643-2651.	0.7	64
424	The New American Joint Committee on Cancer/International Union Against Cancer Staging System for Adenocarcinoma of the Stomach: Increased Complexity without Clear Improvement in Predictive Accuracy. Annals of Surgical Oncology, 2012, 19, 2443-2451.	0.7	57
425	Ki-67 is a Prognostic Biomarker of Survival after Radiofrequency Ablation of Liver Malignancies. Annals of Surgical Oncology, 2012, 19, 4262-4269.	0.7	62
426	Synchronous Resection of Primary and Liver Metastases for Neuroendocrine Tumors. Annals of Surgical Oncology, 2012, 19, 4270-4277.	0.7	60
427	Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies. Cell, 2012, 148, 362-375.	13.5	369
428	Discussions. Biometrics, 2012, 68, 215-216.	0.8	0
429	Impact of Obesity and Body Fat Distribution on Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 2908-2916.	0.7	45
430	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1079-1089.	13.9	1,688
431	Is Port Site Resection Necessary in the Surgical Management of Gallbladder Cancer?. Annals of Surgical Oncology, 2012, 19, 409-417.	0.7	118
432	Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 2012, 489, 155-159.	13.7	320

MITHAT GöNEN

#	Article	IF	CITATIONS
433	Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood, 2012, 119, 4480-4485.	0.6	189
434	Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis. Journal of Surgical Oncology, 2012, 106, 84-88.	0.8	19
435	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer, 2012, 118, 5414-5423.	2.0	33
436	RT-PCR Increases Detection of Submicroscopic Peritoneal Metastases in Gastric Cancer and Has Prognostic Significance. Journal of Gastrointestinal Surgery, 2012, 16, 889-896.	0.9	20
437	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. European Urology, 2012, 61, 237-242.	0.9	69
438	Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery, 2012, 151, 162-170.	1.0	30
439	The outcome of resected cystic pancreatic endocrine neoplasms: A case-matched analysis. Surgery, 2012, 151, 518-525.	1.0	55
440	Biliary Sclerosis after Hepatic Arterial Infusion Pump Chemotherapy for Patients with Colorectal Cancer Liver Metastasis: Incidence, Clinical Features, and Risk Factors. Annals of Surgical Oncology, 2012, 19, 1609-1617.	0.7	73
441	Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter. PLoS ONE, 2012, 7, e41647.	1.1	23
442	Use of detailed pathologic characteristics of the primary colorectal tumor to predict outcome after hepatectomy for metastases Journal of Clinical Oncology, 2012, 30, 559-559.	0.8	1
443	Significance of CEACAM6 expression in biliary tract carcinoma Journal of Clinical Oncology, 2012, 30, 207-207.	0.8	0
444	Abstract 3961: Computational modeling of pancreatic cancer reveals growth and dissemination kinetics and suggests optimum treatment strategies. , 2012, , .		1
445	A prognostic nomogram for prediction of recurrence following surgical resection of desmoid tumors Journal of Clinical Oncology, 2012, 30, 10015-10015.	0.8	0
446	Effect of perioperative complications on recurrence and survival after resection of hepatic colorectal metastases: Analysis of data from a randomized controlled trial Journal of Clinical Oncology, 2012, 30, 3620-3620.	0.8	1
447	Is there any significant difference between tumor regression grade systemsÂof rectal cancer?. Journal of Clinical Oncology, 2012, 30, 3583-3583.	0.8	0
448	A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. Gastrointestinal Cancer Research: GCR, 2012, 5, 185-9.	0.8	7
449	CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy. Journal of Vascular and Interventional Radiology, 2011, 22, 755-761.	0.2	102
450	Difference in Clinical Characteristics and Survival Outcomes in Asian and American Patients With Hepatocellular Carcinoma. Gastroenterology, 2011, 140, S-1003.	0.6	0

#	Article	IF	CITATIONS
451	Irreversible Electroporation Near the Heart: Ventricular Arrhythmias Can Be Prevented With ECG Synchronization. American Journal of Roentgenology, 2011, 196, W330-W335.	1.0	166
452	[18F]FDG-Positron Emission Tomography Coregistration With Computed Tomography Scans for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies. International Journal of Radiation Oncology Biology Physics, 2011, 81, 615-622.	0.4	69
453	Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma. American Journal of Surgical Pathology, 2011, 35, 447-454.	2.1	82
454	A Predictive Model for Lymph Node Yield in Colon Cancer Resection Specimens. Annals of Surgery, 2011, 253, 318-322.	2.1	45
455	Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2011, 254, 851-856.	2.1	100
456	18F-FDG Uptake and Calcifications in the Thoracic Aorta on Positron Emission Tomography/Computed Tomography Examinations. Journal of Thoracic Imaging, 2011, 26, 54-62.	0.8	36
457	Risk of Perioperative Transfusion in Elective Hepatectomy. Annals of Surgery, 2011, 253, 631.	2.1	Ο
458	Perioperative Transfusion Risk Assessment With Elective Hepatectomy. Annals of Surgery, 2011, 253, 630-631.	2.1	0
459	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood, 2011, 118, 1622-1631.	0.6	65
460	Accurate Staging for Gallbladder Cancer. Annals of Surgery, 2011, 254, 320-325.	2.1	186
461	Bias, Biostatistics, and Prognostic Factors. Journal of Thoracic Oncology, 2011, 6, S1705-S1709.	0.5	7
462	The role of laparoscopic staging in patients with incidental gallbladder cancer. Hpb, 2011, 13, 463-472.	0.1	72
463	Liver angiomyolipomas: A clinical, radiologic, and pathologic analysis ofÂ22 patients from a single center. Surgery, 2011, 150, 557-567.	1.0	8
464	Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. Journal of Controlled Release, 2011, 149, 292-298.	4.8	36
465	Gallbladder Cancer: Differences in Presentation, Surgical Treatment, and Survival in Patients Treated at Centers in Three Countries. Journal of the American College of Surgeons, 2011, 212, 50-61.	0.2	100
466	Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-Year Time Period. Journal of the American College of Surgeons, 2011, 212, 590-600.	0.2	210
467	Folate receptor- \hat{I}_{\pm} expression in resectable hepatic colorectal cancer metastases: patterns and significance. Modern Pathology, 2011, 24, 1221-1228.	2.9	48
468	Pancreatic Cyst Fluid and Serum Mucin Levels Predict Dysplasia in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgical Oncology, 2011, 18, 199-206.	0.7	93

MITHAT GöNEN

#	Article	IF	CITATIONS
469	Effect on Outcome of Recurrence Patterns After Hepatectomy for Colorectal Metastases. Annals of Surgical Oncology, 2011, 18, 1096-1103.	0.7	162
470	Treatment and Outcome of Patients with Gastric Remnant Cancer After Resection for Peptic Ulcer Disease. Annals of Surgical Oncology, 2011, 18, 670-676.	0.7	57
471	Laparoscopic Versus Open Gastric Resections for Primary Gastrointestinal Stromal Tumors (GISTs): A Size-Matched Comparison. Annals of Surgical Oncology, 2011, 18, 1599-1605.	0.7	160
472	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. Annals of Surgical Oncology, 2011, 18, 2192-2199.	0.7	76
473	A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs, 2011, 29, 1004-1012.	1.2	38
474	Novel handheld PET probes provide intraoperative localization of PET-avid lymph nodes. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 3214-3221.	1.3	4
475	Solid Pseudopapillary Tumors of the Pancreas. Clinical Features, Surgical Outcomes, and Long-Term Survival in 45 Consecutive Patients from a Single Center. Journal of Gastrointestinal Surgery, 2011, 15, 350-357.	0.9	160
476	An Analysis of the Utility of Handheld PET Probes for the Intraoperative Localization of Malignant Tissue. Journal of Gastrointestinal Surgery, 2011, 15, 358-366.	0.9	13
477	Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. Journal of Translational Medicine, 2011, 9, 36.	1.8	42
478	Assessing noninferiority in a threeâ€arm trial using the Bayesian approach. Statistics in Medicine, 2011, 30, 1795-1808.	0.8	26
479	³¹ P MR spectroscopic imaging detects regenerative changes in human liver stimulated by portal vein embolization. Journal of Magnetic Resonance Imaging, 2011, 34, 336-344.	1.9	4
480	Evaluation of Renal Masses With Contrast-Enhanced Ultrasound: Initial Experience. American Journal of Roentgenology, 2011, 197, 897-906.	1.0	90
481	Pulmonary Thermal Ablation in Patients With Prior Pneumonectomy. American Journal of Roentgenology, 2011, 196, W606-W612.	1.0	36
482	Predicting Survival After Curative Colectomy for Cancer: Individualizing Colon Cancer Staging. Journal of Clinical Oncology, 2011, 29, 4796-4802.	0.8	150
483	Implementation of Evidence-Based Guidelines for Thyroid Nodule Biopsy: A Model for Establishment of Practice Standards. American Journal of Roentgenology, 2011, 196, 655-660.	1.0	60
484	¹²⁴ I-huA33 Antibody PET of Colorectal Cancer. Journal of Nuclear Medicine, 2011, 52, 1173-1180.	2.8	85
485	Challenging the Feasibility and Clinical Significance of Current Guidelines on Lymph Node Examination in Rectal Cancer in the Era of Neoadjuvant Therapy. Journal of Clinical Oncology, 2011, 29, 4568-4573.	0.8	80
486	Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results. Oncology, 2011, 80, 153-159.	0.9	66

#	Article	IF	CITATIONS
487	Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. Journal of Nuclear Medicine, 2011, 52, 1727-1732.	2.8	46
488	A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 2484-2492.	3.2	134
489	The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors. Journal of Clinical Investigation, 2011, 121, 2723-2735.	3.9	777
490	Adequate Lymph Node Assessment for Extrahepatic Bile Duct Adenocarcinoma. Annals of Surgery, 2010, 251, 675-681.	2.1	129
491	Relationship Between Intraoperative Fluid Administration and Perioperative Outcome After Pancreaticoduodenectomy. Annals of Surgery, 2010, 252, 952-958.	2.1	104
492	Comparison of Gastric Cancer Survival Following RO Resection in the United States and Korea Using an Internationally Validated Nomogram. Annals of Surgery, 2010, 251, 640-646.	2.1	314
493	Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set. American Journal of Surgical Pathology, 2010, 34, 300-313.	2.1	312
494	Close Distal Margin and Rectal Cancer Recurrence After Sphincter-Preserving Rectal Resection. Diseases of the Colon and Rectum, 2010, 53, 1365-1373.	0.7	65
495	Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemotherapy and Pharmacology, 2010, 66, 245-254.	1.1	33
496	A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology, 2010, 66, 1113-1121.	1.1	25
497	Whither TNM?. Seminars in Oncology, 2010, 37, 27-30.	0.8	10
498	Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution. Journal of the American College of Surgeons, 2010, 210, 744-752.	0.2	425
499	Laparoscopic Distal Pancreatectomy: Evolution of a Technique at a Single Institution. Journal of the American College of Surgeons, 2010, 211, 503-509.	0.2	168
500	Stage IV breast cancer in the era of targeted therapy. Cancer, 2010, 116, 1226-1233.	2.0	165
501	Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer. Cancer, 2010, 116, 2560-2570.	2.0	136
502	A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer. Cancer, 2010, 116, 3338-3347.	2.0	8
503	Allergies, obesity, other risk factors and survival from pancreatic cancer. International Journal of Cancer, 2010, 127, 2412-2419.	2.3	66
504	T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. Hpb, 2010, 12, 674-683.	0.1	75

#	Article	IF	CITATIONS
505	Antiplatelet Medications Increase the Risk of Post-Polypectomy Bleeding. American Journal of Gastroenterology, 2010, 105, S391-S392.	0.2	4
506	Simple Measurement of Intra-abdominal Fat for Abdominal Surgery Outcome Prediction. Archives of Surgery, 2010, 145, 1069.	2.3	48
507	Assessing the Performance of Prediction Models. Epidemiology, 2010, 21, 128-138.	1.2	3,387
508	¹⁸ F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis. Journal of Nuclear Medicine, 2010, 51, 543-550.	2.8	86
509	Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes. Clinical Cancer Research, 2010, 16, 719-726.	3.2	46
510	Optimal waist:height ratio cut-off point for cardiometabolic risk factors in Turkish adults. Public Health Nutrition, 2010, 13, 488-495.	1.1	18
511	Discovering modulators of gene expression. Nucleic Acids Research, 2010, 38, 5648-5656.	6.5	34
512	Anthropometric indices and their relationship with cardiometabolic risk factors in a sample of Turkish adults – Corrigendum. Public Health Nutrition, 2010, 14, 189-189.	1.1	0
513	Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. Journal of Clinical Investigation, 2010, 120, 636-644.	3.9	299
514	Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. Clinical Cancer Research, 2010, 16, 6093-6099.	3.2	130
515	¹⁸ F-FDG PET/CT for the Prediction and Detection of Local Recurrence After Radiofrequency Ablation of Malignant Lung Lesions. Journal of Nuclear Medicine, 2010, 51, 1833-1840.	2.8	68
516	Progenitor stem cell marker expression by pulmonary carcinomas. Modern Pathology, 2010, 23, 889-895.	2.9	56
517	Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma. Molecular Cancer Therapeutics, 2010, 9, 2761-2769.	1.9	33
518	Characterization of T-Cell Lymphomas by FDG PET/CT. American Journal of Roentgenology, 2010, 195, 333-340.	1.0	95
519	Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System. Thyroid, 2010, 20, 1341-1349.	2.4	785
520	The Bayesian t-Test and Beyond. Methods in Molecular Biology, 2010, 620, 179-199.	0.4	5
521	The Effect of Posttherapy ¹³¹ I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2010, 51, 1361-1367.	2.8	102
522	891d: Antiplatelet Medications Increase the Risk of Post-Polypectomy Bleeding. Gastrointestinal Endoscopy, 2010, 71, AB138.	0.5	2

#	Article	IF	CITATIONS
523	Lehmann Family of ROC Curves. Medical Decision Making, 2010, 30, 509-517.	1.2	27
524	HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. Journal of Clinical Investigation, 2010, 120, 3578-3593.	3.9	162
525	Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 2245-2252.	0.8	19
526	Bayesian clinical trials: no more excuses. Clinical Trials, 2009, 6, 203-204.	0.7	19
527	Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 7405-7411.	3.2	44
528	Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer. Journal of Clinical Oncology, 2009, 27, 6166-6171.	0.8	82
529	Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation. Journal of Nuclear Medicine, 2009, 50, 1605-1610.	2.8	106
530	Use of Helical CT Is Associated with an Increased Incidence of Postoperative Pulmonary Emboli in Cancer Patients with No Change in the Number of Fatal Pulmonary Emboli. Journal of the American College of Surgeons, 2009, 208, 871-878.	0.2	53
531	Molecular network pathway and functional analysis of tumor signatures associated with development of resistance to viral gene therapy. Journal of the American College of Surgeons, 2009, 209, S51.	0.2	0
532	Clinical benefits of a multivariate prediction model for bladder cancer. Cancer, 2009, 115, 5460-5469.	2.0	32
533	Patients with chemotherapyâ€refractory mantle cell lymphoma experience high response rates and identical progressionâ€free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. British Journal of Haematology, 2009, 145, 34-39.	1.2	72
534	Prognostic Impact of RT-PCR-Based Detection of Peritoneal Micrometastases in Patients with Pancreatic Cancer Undergoing Curative Resection. Annals of Surgical Oncology, 2009, 16, 3333-3339.	0.7	34
535	Positive Nonsentinel Node Status Predicts Mortality in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2009, 16, 186-90.	0.7	61
536	Synchronous Hepatic Metastases from Colon Cancer: Changing Treatment Strategies and Results of Surgical Intervention. Annals of Surgical Oncology, 2009, 16, 361-370.	0.7	39
537	Laparoscopic Versus Open Subtotal Gastrectomy for Adenocarcinoma: A Case–Control Study. Annals of Surgical Oncology, 2009, 16, 1507-1513.	0.7	170
538	Liver Resection for Metastatic Colorectal Cancer in Patients with Concurrent Extrahepatic Disease: Results in 127 Patients Treated at a Single Center. Annals of Surgical Oncology, 2009, 16, 2138-2146.	0.7	145
539	T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2009, 16, 2524-2530.	0.7	116
540	Human Liver Dendritic Cells Promote T Cell Hyporesponsiveness. Journal of Immunology, 2009, 182, 1901-1911.	0.4	186

#	Article	IF	CITATIONS
541	A simulation study to evaluate the impact of the number of lesions measured on response assessment. European Journal of Cancer, 2009, 45, 300-310.	1.3	51
542	A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology, 2009, 9, 404-409.	0.5	37
543	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncology, The, 2009, 10, 1045-1052.	5.1	430
544	Long-Term Survival After Transanal Excision of T1 Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 577-582.	0.7	151
545	Predicting the Risk of Perioperative Transfusion for Patients Undergoing Elective Hepatectomy. Annals of Surgery, 2009, 250, 914-921.	2.1	83
546	Operative Blood Loss Independently Predicts Recurrence and Survival After Resection of Hepatocellular Carcinoma. Annals of Surgery, 2009, 249, 617-623.	2.1	355
547	Perineural Invasion After Preoperative Chemotherapy Predicts Poor Survival in Patients With Locally Advanced Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 356-362.	0.6	18
548	Anthropometric indices and their relationship with cardiometabolic risk factors in a sample of Turkish adults. Public Health Nutrition, 2009, 12, 538.	1.1	46
549	Statistical aspects of gene signatures and molecular targets. Gastrointestinal Cancer Research: GCR, 2009, 3, S19-21.	0.8	10
550	Pancreatic Adenocarcinoma: The Actual 5-Year Survivors. Journal of Gastrointestinal Surgery, 2008, 12, 701-706.	0.9	224
551	Preoperative Predictors for Complications after Pancreaticoduodenectomy: Impact of BMI and Body Fat Distribution. Journal of Gastrointestinal Surgery, 2008, 12, 270-278.	0.9	241
552	Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer, 2008, 11, 206-213.	2.7	42
553	Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy. Diseases of the Colon and Rectum, 2008, 51, 503-507.	0.7	211
554	Bayesian modeling of multivariate average bioequivalence. Statistics in Medicine, 2008, 27, 2402-2419.	0.8	20
555	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112, 608-615.	2.0	437
556	Pathologic stage is most prognostic of diseaseâ€free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer, 2008, 113, 57-64.	2.0	228
557	Clinical Significance of Intraoperative Bile Duct Margin Assessment for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2008, 15, 2104-2112.	0.7	111
558	Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. Annals of Surgical Oncology, 2008, 15, 2894-2902.	0.7	68

#	Article	IF	CITATIONS
559	Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2008, 15, 3512-3520.	0.7	168
560	Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. Hpb, 2008, 10, 341-346.	0.1	40
561	Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Medical Informatics and Decision Making, 2008, 8, 53.	1.5	966
562	Effects of Pathologic Stage on the Learning Curve for Radical Prostatectomy: Evidence That Recurrence in Organ-Confined Cancer Is Largely Related to Inadequate Surgical Technique. European Urology, 2008, 53, 960-966.	0.9	100
563	A Novel Prognostic Nomogram Is More Accurate than Conventional Staging Systems for Predicting Survival after Resection of Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2008, 206, 281-291.	0.2	114
564	Current Utility of Staging Laparoscopy for Pancreatic and Peripancreatic Neoplasms. Journal of the American College of Surgeons, 2008, 206, 445-450.	0.2	109
565	CLINICAL BENEFITS OF A MULTIVARIABLE PREDICTION MODEL FOR BLADDER CANCER: A DECISION ANALYTIC APPROACH. Journal of Urology, 2008, 179, 320-320.	0.2	1
566	Immunohistochemical expression of folate receptor \hat{I}_{\pm} in colorectal carcinoma: patterns and biological significance. Human Pathology, 2008, 39, 498-505.	1.1	102
567	The prediction philosophy in statistics. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 316-319.	0.8	6
568	Individualized Prediction of Colon Cancer Recurrence Using a Nomogram. Journal of Clinical Oncology, 2008, 26, 380-385.	0.8	244
569	Disenrollment From Medicare Managed Care Among Beneficiaries With and Without a Cancer Diagnosis. Journal of the National Cancer Institute, 2008, 100, 1013-1021.	3.0	8
570	Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel. Cancer Research, 2008, 68, 589-596.	0.4	172
571	A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors. Clinical Cancer Research, 2008, 14, 6704-6711.	3.2	59
572	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using ¹¹¹ In-J591: Lesion Detectability and Dosimetric Projections for ⁹⁰ Y Radioimmunotherapy. Journal of Nuclear Medicine, 2008, 49, 1066-1074.	2.8	76
573	Area Between Curves: What You See Is Not What You Get. Journal of Clinical Oncology, 2008, 26, 2236-2236.	0.8	3
574	Histopathologic and Immunohistochemical Features of Tissue Adherent to Multitined Electrodes after RF Ablation of Liver Malignancies Can Help Predict Local Tumor Progression: Initial Results. Radiology, 2008, 249, 364-374.	3.6	59
575	Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 2008, 111, 5350-5358.	0.6	131
576	The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 2008, 112, 2906-2916.	0.6	119

#	Article	IF	CITATIONS
577	Effect of Postoperative Morbidity on Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2008, 247, 994-1002.	2.1	201
578	Increased Use of Parenchymal-Sparing Surgery for Bilateral Liver Metastases From Colorectal Cancer Is Associated With Improved Mortality Without Change in Oncologic Outcome. Annals of Surgery, 2008, 247, 109-117.	2.1	215
579	Impact of Margin Width on Outcome After Resection of Colorectal Liver Metastases. Annals of Surgery, 2008, 247, 905-906.	2.1	0
580	Evaluation of Different Methods of 18F-FDG-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 439-445.	0.6	38
581	A Nomogram for Predicting Disease-specific Survival After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2008, 247, 282-287.	2.1	154
582	A Prospective Randomized Trial of Acute Normovolemic Hemodilution Compared to Standard Intraoperative Management in Patients Undergoing Major Hepatic Resection. Annals of Surgery, 2008, 248, 360-369.	2.1	134
583	Intrahepatic Cholangiocarcinoma. Annals of Surgery, 2008, 248, 84-96.	2.1	729
584	Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Blood, 2008, 112, 3244-3244.	0.6	1
585	Modelling BCR-ABL1 Dynamics in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) during Frontline Therapy with High-Dose Imatinib, Nilotinib, or Dasatinib Blood, 2008, 112, 3240-3240.	0.6	Ο
586	Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure. Journal of Clinical Oncology, 2007, 25, 4575-4580.	0.8	1,047
587	The Development and Execution of Medical Prediction Models. , 2007, , 443-455.		Ο
588	Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study. Journal of Clinical Oncology, 2007, 25, 4557-4561.	0.8	406
589	Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels. Journal of Nuclear Medicine, 2007, 48, 501-507.	2.8	142
590	Determining Prognosis in Patients With Pancreatic Endocrine Neoplasms: Can the WHO Classification System Be Simplified?. Journal of Clinical Oncology, 2007, 25, 5609-5615.	0.8	163
591	Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery, 2007, 245, 347-352.	2.1	273
592	The Impact of Margins on Outcome After Hepatic Resection for Colorectal Metastasis. Annals of Surgery, 2007, 246, 295-300.	2.1	207
593	Adenocarcinoma of the Gastroesophageal Junction. Annals of Surgery, 2007, 246, 1-8.	2.1	203
594	Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncology, The, 2007, 8, 304-310.	5.1	370

#	Article	IF	CITATIONS
595	Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2007, 14, 134-142.	0.7	104
596	Predictive Molecular Markers for Colorectal Cancer Patients With Resected Liver Metastasis and Adjuvant Chemotherapy. Gastroenterology, 2007, 133, 1831-1839.	0.6	18
597	Adjuvant Chemotherapy Improves Survival after Resection of Hepatic Colorectal Metastases: Analysis of Data from Two Continents. Journal of the American College of Surgeons, 2007, 204, 753-761.	0.2	175
598	Outcomes after Resection of Synchronous or Metachronous Hepatic and Pulmonary Colorectal Metastases. Journal of the American College of Surgeons, 2007, 205, 231-238.	0.2	192
599	Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 1419-1427.e4.	0.4	58
600	Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy. Annals of Surgical Oncology, 2007, 14, 1151-1160.	0.7	138
601	Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Annals of Surgical Oncology, 2007, 14, 759-765.	0.7	161
602	Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Annals of Surgical Oncology, 2007, 14, 306-316.	0.7	71
603	Laparoscopic Adrenalectomy for Isolated Adrenal Metastasis. Annals of Surgical Oncology, 2007, 14, 3392-3400.	0.7	194
604	Utility of a Prognostic Nomogram Designed for Gastric Cancer in Predicting Outcome of Patients with R0 Resected Duodenal Adenocarcinoma. Annals of Surgical Oncology, 2007, 14, 3159-3167.	0.7	17
605	Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer?. Annals of Surgical Oncology, 2007, 14, 3412-3418.	0.7	95
606	Autologous Versus Allogeneic Transfusions: No Difference in Perioperative Outcome After Partial Hepatectomy. Journal of Gastrointestinal Surgery, 2007, 11, 1286-1293.	0.9	14
607	Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2007, 11, 1549-1555.	0.9	176
608	Detection of Micrometastases in Peritoneal Washings of Pancreatic Cancer Patients by the Reverse Transcriptase Polymerase Chain Reaction. Journal of Gastrointestinal Surgery, 2007, 11, 1598-1606.	0.9	13
609	1398: Effects of Patient Risk on the Learning Curve for Radical Prostatectomy: Evidence that Recurrence in Organ-Confined Cancer is Largely Related to Inadequate Surgical Technique. Journal of Urology, 2007, 177, 460-460.	0.2	3
610	Preoperative 18[F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival After Esophageal Adenocarcinoma Resection. Annals of Thoracic Surgery, 2006, 81, 1076-1081.	0.7	118
611	Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. International Journal of Oncology, 2006, 28, 1429.	1.4	2
612	Evidence-Based Gallbladder Cancer Staging. Annals of Surgery, 2006, 243, 767-774.	2.1	106

#	Article	IF	CITATIONS
613	Perihepatic Lymph Node Assessment in Patients Undergoing Partial Hepatectomy for Malignancy. Annals of Surgery, 2006, 244, 260-264.	2.1	106
614	A Selective Approach to the Resection of Cystic Lesions of the Pancreas. Transactions of the Meeting of the American Surgical Association, 2006, 124, 237-247.	2.8	140
615	Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. British Journal of Haematology, 2006, 134, 391-398.	1.2	55
616	Utility of Preoperative [(18)]F Fluorodeoxyglucose–Positron Emission Tomography Scanning in High-Risk Melanoma Patients. Annals of Surgical Oncology, 2006, 13, 525-532.	0.7	83
617	18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Scanning Affects Surgical Management in Selected Patients With High-Risk, Operable Breast Carcinoma. Annals of Surgical Oncology, 2006, 13, 677-684.	0.7	43
618	Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2006, 13, 353-362.	0.7	59
619	Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus. Molecular Imaging and Biology, 2006, 8, 30-35.	1.3	13
620	Optimal Abdominal Incision for Partial Hepatectomy: Increased Late Complications with Mercedes-type Incisions Compared to Extended Right Subcostal Incisions. World Journal of Surgery, 2006, 30, 410-418.	0.8	56
621	Differential diagnosis of proximal biliary obstruction. Surgery, 2006, 140, 756-763.	1.0	55
622	Positron emission tomography predicts survival in malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 763-768.	0.4	136
623	The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2006, 12, 924-932.	3.2	66
624	Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 498-505.	1.8	513
625	Functional Assessment of the Engraftment Potential of Gammaretrovirus-Modified CD34+Cells, Using a Short Serum-Free Transduction Protocol. Human Gene Therapy, 2006, 17, 780-794.	1.4	8
626	Differential Cell Cycle–Regulatory Protein Expression in Biliary Tract Adenocarcinoma: Correlation With Anatomic Site, Pathologic Variables, and Clinical Outcome. Journal of Clinical Oncology, 2006, 24, 1152-1160.	0.8	80
627	Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. International Journal of Oncology, 2006, 28, 1429-39.	1.4	5
628	Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. Journal of Nuclear Medicine, 2006, 47, 1260-6.	2.8	89
629	Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology. American Journal of Surgical Pathology, 2005, 29, 305-317.	2.1	178
630	Free Tissue Transfer in the Elderly: Incidence of Perioperative Complications following Microsurgical Reconstruction of 197 Septuagenarians and Octogenarians. Plastic and Reconstructive Surgery, 2005, 116, 1659-1668.	0.7	120

#	Article	IF	CITATIONS
631	Long-Term Survival Is Superior After Resection for Cancer in High-Volume Centers. Annals of Surgery, 2005, 242, 540-547.	2.1	352
632	Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram. Annals of Surgical Oncology, 2005, 12, 654-659.	0.7	211
633	2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 4761-4769.	3.2	210
634	A Standardized Regimen of Antibiotics Prevents Infectious Complications in Skull Base Surgery. Laryngoscope, 2005, 115, 1347-1357.	1.1	50
635	Caudate hepatectomy for cancer: A single institution experience with 150 patients. Journal of the American College of Surgeons, 2005, 200, 345-352.	0.2	68
636	Is Detection of Asymptomatic Recurrence after Curative Resection Associated with Improved Survival in Patients with Gastric Cancer?. Journal of the American College of Surgeons, 2005, 201, 503-510.	0.2	59
637	Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer, 2005, 103, 2575-2583.	2.0	72
638	Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer, 2005, 104, 1948-1955.	2.0	123
639	Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. Journal of Surgical Oncology, 2005, 91, 97-101.	0.8	41
640	Clinical Value of Combined Positron Emission Tomography/Computed Tomography Imaging in the Interpretation of 2-Deoxy-2-[F-18]fluoro-d-glucose–Positron Emission Tomography Studies in Cancer Patients. Molecular Imaging and Biology, 2005, 7, 229-235.	1.3	47
641	Planning a dose–response study with subject-specific doses. Statistics in Medicine, 2005, 24, 2613-2623.	0.8	1
642	A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. Clinical Cancer Research, 2005, 11, 3836-3845.	3.2	109
643	Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. Clinical Cancer Research, 2005, 11, 3296-3302.	3.2	61
644	Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 8055-8062.	3.2	325
645	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2005, 23, 1875-1884.	0.8	113
646	Hepatic Arterial Infusion after Liver Resection. New England Journal of Medicine, 2005, 352, 734-735.	13.9	210
647	Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 4888-4896.	0.8	201
648	VALIDATION OF A NOMOGRAM FOR PREDICTING POSITIVE REPEAT BIOPSY FOR PROSTATE CANCER. Journal of Urology, 2005, 173, 421-424.	0.2	73

#	Article	IF	CITATIONS
649	Concordance probability and discriminatory power in proportional hazards regression. Biometrika, 2005, 92, 965-970.	1.3	539
650	Comparison of Survival Rates after Bland Arterial Embolization and Ablation Versus Surgical Resection for Treating Solitary Hepatocellular Carcinoma up to 7 cm. Journal of Vascular and Interventional Radiology, 2005, 16, 955-961.	0.2	86
651	Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 4643-4651.	0.8	462
652	A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. Contemporary Clinical Trials, 2005, 26, 131-140.	0.8	17
653	The Bayesian Two-SampletTest. American Statistician, 2005, 59, 252-257.	0.9	74
654	Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET. American Journal of Roentgenology, 2004, 183, 1143-1147.	1.0	54
655	Phase I Trial of Combined-Modality Therapy for Localized Esophageal Cancer: Escalating Doses of Continuous-Infusion Paclitaxel With Cisplatin and Concurrent Radiation Therapy. Journal of Clinical Oncology, 2004, 22, 45-52.	0.8	66
656	Infection with Oncolytic Herpes Simplex Virus-1 Induces Apoptosis in Neighboring Human Cancer Cells. Clinical Cancer Research, 2004, 10, 3225-3232.	3.2	53
657	Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection. Journal of Clinical Oncology, 2004, 22, 3255-3260.	0.8	339
658	Selective use of diagnostic laparoscopy prior to planned hepatectomy for patients with hepatocellular carcinoma. Surgery, 2004, 135, 273-281.	1.0	34
659	Sample size and power for McNemar's test with clustered data. Statistics in Medicine, 2004, 23, 2283-2294.	0.8	11
660	The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer, 2004, 100, 2655-2663.	2.0	181
661	Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. Journal of Surgical Oncology, 2004, 87, 85-90.	0.8	6
662	Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. Radiology, 2004, 231, 65-72.	3.6	372
663	Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. Clinical Cancer Research, 2004, 10, 3282-3290.	3.2	194
664	Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma. Annals of Surgery, 2004, 240, 808-816.	2.1	514
665	Prognostic value of [18 F]FDC-PET imaging in small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 78-84.	3.3	151
666	Planning for subgroup analysis: a case study of treatment-marker interaction in metastatic colorectal cancer. Contemporary Clinical Trials, 2003, 24, 355-363.	2.0	11

#	Article	IF	CITATIONS
667	Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 11-15.	0.4	208
668	Impact of steatosis on perioperative outcome following hepatic resection. Journal of Gastrointestinal Surgery, 2003, 7, 1034-1044.	0.9	387
669	Volumetric Analysis Predicts Hepatic Dysfunction in Patients Undergoing Major Liver Resection. Journal of Gastrointestinal Surgery, 2003, 7, 325-330.	0.9	433
670	Bayesian Multiple Testing for Two-Sample Multivariate Endpoints. Biometrics, 2003, 59, 76-82.	0.8	12
671	Surgical exposure for partial hepatectomy: Is there a difference in complications from the Chevron versus the hockey stick incision?. Gastroenterology, 2003, 124, A825.	0.6	Ο
672	Predictors of early versus late mortality after resection of hepatocellular carcinoma. Gastroenterology, 2003, 124, A825-A826.	0.6	0
673	Variations Among Individual Surgeons in the Rate of Positive Surgical Margins in Radical Prostatectomy Specimens. Journal of Urology, 2003, 170, 2292-2295.	0.2	311
674	Vascular inflow control during hepatic lobectomy: a comparison of intrahepatic pedicle ligation versus extrahepatic ligation. Gastroenterology, 2003, 124, A824.	0.6	0
675	A Nomogram For Predicting a Positive Repeat Prostate Biopsy in Patients With a Previous Negative Biopsy Session. Journal of Urology, 2003, 170, 1184-1188.	0.2	88
676	Hepatic steatosis is associated with increased complications following major liver resection for cancer but does not impact survival. Gastroenterology, 2003, 124, A794.	0.6	7
677	Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2003, 21, 406-412.	0.8	76
678	Interaction of Splenectomy and Perioperative Blood Transfusions on Prognosis of Patients With Proximal Gastric and Gastroesophageal Junction Cancer. Journal of Clinical Oncology, 2003, 21, 4597-4603.	0.8	41
679	Whole Body18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial. Journal of Clinical Oncology, 2003, 21, 428-432.	0.8	338
680	Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer. Journal of Clinical Oncology, 2003, 21, 2926-2932.	0.8	96
681	Title is missing!. Annals of Surgery, 2003, 237, 860-870.	2.1	52
682	Influence of Transfusions on Perioperative and Long-Term Outcome in Patients Following Hepatic Resection for Colorectal Metastases. Annals of Surgery, 2003, 237, 860-870.	2.1	493
683	Sonohysterography Compared With Endometrial Biopsy for Evaluation of the Endometrium in Tamoxifenâ€Treated Women. Journal of Ultrasound in Medicine, 2003, 22, 1173-1179.	0.8	18
684	Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors. Journal of Clinical Oncology, 2002, 20, 4673-4678.	0.8	268

#	ARTICLE	IF	CITATIONS
685	Second Liver Resections Are Safe and Effective Treatment for Recurrent Hepatic Metastases from Colorectal Cancer. Annals of Surgery, 2002, 235, 863-871.	2.1	284
686	Improvement in Perioperative Outcome After Hepatic Resection. Annals of Surgery, 2002, 236, 397-407.	2.1	1,229
687	An initial experience with FDC-PET in the imaging of residual disease after induction therapy for lung cancer. Annals of Thoracic Surgery, 2002, 73, 259-266.	0.7	150
688	Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery, 2002, 132, 353-359.	1.0	60
689	An optimal two-stage phase II design utilizing complete and partial response information separately. Contemporary Clinical Trials, 2002, 23, 367-379.	2.0	26
690	The management of variant arterial anatomy during hepatic arterial infusion pump placement. Annals of Surgical Oncology, 2002, 9, 875-880.	0.7	64
691	Comparisons of nomograms and urologists' predictions in prostate cancer. Urologic Oncology, 2002, 20, 82-88.	1.5	214
692	Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Annals of Surgery, 2002, 236, 397-406; discussion 406-7.	2.1	769
693	Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. Journal of Nuclear Medicine, 2002, 43, 46-55.	2.8	120
694	FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 155-164.	2.2	124
695	Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma. Annals of Surgery, 2001, 234, 507-519.	2.1	1,153
696	Complications of Type I Thyroplasty and Arytenoid Adduction. Laryngoscope, 2001, 111, 1322-1329.	1.1	120
697	Statistical Issues in Analysis of Diagnostic Imaging Experiments with Multiple Observations per Patient. Radiology, 2001, 221, 763-767.	3.6	98
698	The Limiting Density of Unit Root Test Statistics: A Unifying Technique. Journal of Time Series Analysis, 2000, 21, 249-260.	0.7	1
699	A bayesian analysis of the intraclass correlations in the mixed linear model. Communications in Statistics - Theory and Methods, 2000, 29, 1451-1464.	0.6	2
700	Asymptotic properties of anoya bayes factors. Communications in Statistics - Theory and Methods, 1996, 25, 3101-3123.	0.6	10